Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2022-06-10 Sale |
2022-06-16 4:22 pm |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
407 | $69.61 | $28,331 | 2,537 (Direct) |
View |
| 2022-05-10 Sale |
2022-05-12 4:30 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
4,205 | $63.17 | $265,646 | 34,846 (Direct) |
View |
| 2022-03-09 Sale |
2022-03-11 4:54 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,669 | $71.19 | $261,196 | 86,904 (Direct) |
View |
| 2022-03-07 Sale |
2022-03-09 4:56 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
7,775 | $69.73 | $542,116 | 81,908 (Direct) |
View |
| 2022-03-08 Sale |
2022-03-09 4:55 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
744 | $70.1 | $52,154 | 102,295 (Direct) |
View |
| 2022-03-08 Sale |
2022-03-09 4:53 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
1,037 | $70.1 | $72,694 | 55,991 (Direct) |
View |
| 2022-03-08 Sale |
2022-03-09 4:52 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
2,923 | $70.1 | $204,902 | 165,102 (Direct) |
View |
| 2022-03-08 Sale |
2022-03-09 4:51 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
759 | $70.1 | $53,206 | 60,848 (Direct) |
View |
| 2022-03-08 Sale |
2022-03-09 4:50 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
2,339 | $70.1 | $163,964 | 62,462 (Direct) |
View |
| 2022-03-08 Sale |
2022-03-09 4:48 pm |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Executive Chairman |
2,385 | $70.1 | $167,189 | 552,013 (Direct) |
View |
| 2022-03-03 Sale |
2022-03-07 6:28 pm |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
3,067 | $71.87 | $220,414 | 70,907 (Direct) |
View |
| 2022-03-03 Sale |
2022-03-07 6:26 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,705 | $73.16 | $124,744 | 104,411 (Direct) |
View |
| 2022-03-03 Sale |
2022-03-07 6:23 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
5,543 | $72.54 | $402,064 | 133,941 (Direct) |
View |
| 2022-03-03 Sale |
2022-03-07 6:18 pm |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
2,313 | $71.83 | $166,136 | 79,131 (Direct) |
View |
| 2022-03-03 Sale |
2022-03-07 6:17 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
1,367 | $71.43 | $97,641 | 74,427 (Direct) |
View |
| 2022-03-03 Sale |
2022-03-07 6:16 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
3,870 | $71.78 | $277,797 | 214,079 (Direct) |
View |
| 2022-03-03 Sale |
2022-03-07 6:14 pm |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
1,485 | $72.97 | $108,359 | 138,394 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2022-07-05 Option Award |
2022-07-07 5:48 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
276 | $59.08 | 13,583 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:47 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
222 | $59.08 | 35,068 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:46 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
312 | $59.08 | 102,607 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:45 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
312 | $59.08 | 83,499 (Direct) |
View |
| 2022-07-05 Option Award |
2022-07-07 5:44 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
213 | $59.08 | 56,204 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:12 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | Madden Martin J. Director |
8,700 | $0 | 8,700 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:11 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | Hung David Director |
6,777 | $0 | 13,491 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:10 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | Scannell Timothy J Director |
8,700 | $0 | 8,700 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:10 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | VERNON W ANTHONY Director |
8,700 | $0 | 8,700 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:09 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
6,777 | $0 | 79,636 (Direct) |
View |
| 2022-06-08 Option Award |
2022-06-10 4:08 pm |
N/A 2032-06-08 |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
8,700 | $0 | 8,700 (Direct) |
View |
| 2022-05-05 Gift |
2022-05-09 4:14 pm |
N/A 2026-01-12 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
2,648 | $0 | 147,048 (Indirect) |
View |
Ownership |
2022-04-14 4:36 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
0 | $0 | 50,806 (Direct) |
View |
| 2022-03-03 Exercise |
2022-03-11 4:55 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,200 | $11.46 | 73,624 (Direct) |
View |
| 2022-03-03 Exercise |
2022-03-11 4:55 pm |
N/A 2025-04-22 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
3,840 | $15.6 | 73,624 (Direct) |
View |
| 2021-07-31 Exercise |
2022-03-11 4:54 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,717 | $154.01 | 86,904 (Direct) |
View |
| 2021-07-31 Exercise |
2022-03-11 4:54 pm |
2021-07-31 N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
3,717 | $0 | 86,904 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:28 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | Longsworth Todd Christopher General Counsel |
6,106 | $80.59 | 70,907 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:26 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
21,508 | $0 | 104,411 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:26 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
42,804 | $80.59 | 104,411 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:25 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
17,371 | $0 | 84,569 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:25 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
35,383 | $80.59 | 84,569 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:23 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
21,714 | $0 | 133,941 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:23 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
44,258 | $80.59 | 133,941 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:22 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
13,470 | $80.59 | 13,470 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:21 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | DOYLE WILLIAM F Executive Chairman |
14,581 | $80.59 | 14,581 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
17,371 | $0 | 79,131 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:18 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
35,874 | $80.59 | 79,131 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
7,445 | $0 | 74,427 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:17 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
17,399 | $80.59 | 74,427 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:16 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
21,921 | $0 | 214,079 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:16 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
46,054 | $80.59 | 214,079 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
17,371 | $0 | 138,394 (Direct) |
View |
| 2022-03-03 Option Award |
2022-03-07 6:14 pm |
2023-03-01 2032-02-29 |
NovoCure Ltd | NVCR | Leonard Frank X Chief Development Officer |
35,355 | $80.59 | 138,394 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-12 5:41 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
35 | $63.82 | 31,815 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-12 5:39 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
80 | $63.82 | 50,950 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-12 5:38 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
55 | $63.82 | 28,199 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-12 5:37 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
46 | $63.82 | 41,804 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-12 5:31 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
31 | $63.82 | 13,307 (Direct) |
View |
| 2022-01-06 Option Award |
2022-01-12 5:30 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
75 | $63.82 | 149,974 (Direct) |
View |